226
|
Shaughnessy P, Alexander W, Tran H, Ririe D, Splichal J, Pollack M, Bachier C, LeMaistre C. Phase I and Pharmacokinetic Study of Once-Daily Dosing of Intravenously Administered Busulfan in the Setting of a Reduced-Intensity Preparative Regimen and Allogeneic Hematopoietic Stem Cell Transplantation as Immunotherapy for Renal Cell Carcinoma. Mil Med 2006; 171:161-5. [PMID: 16578989 DOI: 10.7205/milmed.171.2.161] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
We performed a Phase I and pharmacokinetic study of once-daily, intravenously administered busulfan in the setting of a reduced-intensity preparative regimen and matched sibling donor allogeneic stem cell transplantation for treatment of metastatic renal cell carcinoma. Seven male patients with metastatic renal cell carcinoma received intravenously administered busulfan at 3.2 mg/kg once daily on day -10 and day -9, fludarabine at 30 mg/m2 on day -7 through day -2, and equine antithymocyte globulin at 15 mg/kg per day on day -5 through day -2. The mean area under the plasma concentration-time curve (AUC) and the half-life of the first dose of intravenously administered busulfan were 6,253 microM x minute (range, 5,036-7,482 microM x minute) and 3.37 hours (range, 2.54-4.00 hours), respectively. The AUC was higher than predicted from extrapolation of AUC data for the same total dose of intravenously administered busulfan divided into four doses daily. Patients experienced greater than expected regimen-related toxicity for a reduced-intensity preparative regimen, and the study was stopped. In conclusion, this preparative regimen was associated with unacceptable regimen-related toxicity among patients with metastatic renal cell carcinoma.
Collapse
|
227
|
Grosso D, Brunner J, Dessain S, Ferber A, Filicko J, Mookerjee B, Shaw L, Tedesco N, Tran H, Wagner J, Flomenberg N. Amifostine does not protect against liver toxicity in patients receiving dose-escalated IV busulfan (IVBU) and standard dose cyclophosphamide in auto BMT. Biol Blood Marrow Transplant 2006. [DOI: 10.1016/j.bbmt.2005.11.296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
228
|
Wu RH, Guo G, Zhang YP, Tran H, terBrugge K, Mikulis D. Can we use 1H MRS shimming values to obtain 31P spectra? CONFERENCE PROCEEDINGS : ... ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. ANNUAL CONFERENCE 2006; 2006:1873-1876. [PMID: 17946076 DOI: 10.1109/iembs.2006.260792] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
The perfect shimming of 31P magnetic resonance spectroscopy (MRS) is not easy in vivo. The purpose of this study was to examine the feasibility of using 1H MRS shimming values to obtain 31P spectra in a same sequence. Both phantom and volunteer studies were carried out in this study. Phantom was a sphere filled with physiological metabolites of brain. In vivo study was performed on 4 healthy volunteers. The studies were performed on a 3-T GE scanner. A same localizer and a same cursor were used for both 1H and 31P scans. A spin echo MRS sequence was utilized for both 1H scans with a standard head coil and 31P scans with a GE service coil. 1H scan was performed using first and automatic shimming and water linewidth (FWHM) of 3 Hz for phantom and 5 Hz for the volunteer were obtained. Shimming values of 1H scan in x, y, z directions were copied to 31P scan. A routine procedure of 31P scan without value coping was also performed. Spectra were analyzed using SAGE/IDL program. Signal to noise ratio (SNR) was defined as the ratio of the signal height / maximum noise height. Good 1H spectra and 31P spectra were obtained for both phantom and volunteer studies. The 31P spectra with 1H MRS shimming values were similar with the 31P spectra obtained with routine procedure. Lower SNRs of 31P spectra were obtained in phantom with 1H MRS shimming values, compared with routine procedure scan. Average SNR for Pi of 31P spectra was 7.45:1 in the volunteer study with routine procedure, and 7.275:1 with 1H MRS shimming values. 1H MRS shimming values can be used to obtain useful 31P spectra in a same sequence.
Collapse
|
229
|
Tran H, Boulet C, Hartmann JM. Line mixing and collision-induced absorption by oxygen in the A band: Laboratory measurements, model, and tools for atmospheric spectra computations. ACTA ACUST UNITED AC 2006. [DOI: 10.1029/2005jd006869] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
230
|
Lee HY, Oh SH, Woo JK, Kim WY, Van Pelt CS, Price RE, Cody D, Tran H, Pezzuto JM, Moriarty RM, Hong WK. Chemopreventive Effects of Deguelin, a Novel Akt Inhibitor, on Tobacco-Induced Lung Tumorigenesis. ACTA ACUST UNITED AC 2005; 97:1695-9. [PMID: 16288123 DOI: 10.1093/jnci/dji377] [Citation(s) in RCA: 118] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Tobacco carcinogens induce Akt activation and lung carcinogenesis. We previously demonstrated that deguelin, a natural plant product, specifically inhibits the proliferation of premalignant and malignant human bronchial epithelial cells by blocking Akt activation. To evaluate the ability of deguelin to block tobacco carcinogen-induced lung tumorigenesis, we evaluated the in vivo effects of deguelin on Akt activation and lung tumorigenesis in transgenic mice in which Akt expression was induced by tamoxifen and in 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone (NNK)/benzo(a)pyrene (BaP)-treated A/J mice. Deguelin suppressed Akt activation in vivo, as measured by immunohistochemistry and immunoblotting, and statistically significantly reduced NNK/BaP-induced lung tumor multiplicity, volume, and load in A/J mice, as monitored by microcomputed tomography image analysis, with no detectable toxicity. These results indicate that deguelin warrants consideration as a chemopreventive agent for early-stage lung carcinogenesis in a clinical lung cancer chemoprevention trial.
Collapse
|
231
|
Meech KJ, Ageorges N, A'Hearn MF, Arpigny C, Ates A, Aycock J, Bagnulo S, Bailey J, Barber R, Barrera L, Barrena R, Bauer JM, Belton MJS, Bensch F, Bhattacharya B, Biver N, Blake G, Bockelée-Morvan D, Boehnhardt H, Bonev BP, Bonev T, Buie MW, Burton MG, Butner HM, Cabanac R, Campbell R, Campins H, Capria MT, Carroll T, Chaffee F, Charnley SB, Cleis R, Coates A, Cochran A, Colom P, Conrad A, Coulson IM, Crovisier J, deBuizer J, Dekany R, de Léon J, Dello Russo N, Delsanti A, DiSanti M, Drummond J, Dundon L, Etzel PB, Farnham TL, Feldman P, Fernández YR, Filipovic MD, Fisher S, Fitzsimmons A, Fong D, Fugate R, Fujiwara H, Fujiyoshi T, Furusho R, Fuse T, Gibb E, Groussin O, Gulkis S, Gurwell M, Hadamcik E, Hainaut O, Harker D, Harrington D, Harwit M, Hasegawa S, Hergenrother CW, Hirst P, Hodapp K, Honda M, Howell ES, Hutsemékers D, Iono D, Ip WH, Jackson W, Jehin E, Jiang ZJ, Jones GH, Jones PA, Kadono T, Kamath UW, Käufl HU, Kasuga T, Kawakita H, Kelley MS, Kerber F, Kidger M, Kinoshita D, Knight M, Lara L, Larson SM, Lederer S, Lee CF, Levasseur-Regourd AC, Li JY, Li QS, Licandro J, Lin ZY, Lisse CM, LoCurto G, Lovell AJ, Lowry SC, Lyke J, Lynch D, Ma J, Magee-Sauer K, Maheswar G, Manfroid J, Marco O, Martin P, Melnick G, Miller S, Miyata T, Moriarty-Schieven GH, Moskovitz N, Mueller BEA, Mumma MJ, Muneer S, Neufeld DA, Ootsubo T, Osip D, Pandea SK, Pantin E, Paterno-Mahler R, Patten B, Penprase BE, Peck A, Petitas G, Pinilla-Alonso N, Pittichova J, Pompei E, Prabhu TP, Qi C, Rao R, Rauer H, Reitsema H, Rodgers SD, Rodriguez P, Ruane R, Ruch G, Rujopakarn W, Sahu DK, Sako S, Sakon I, Samarasinha N, Sarkissian JM, Saviane I, Schirmer M, Schultz P, Schulz R, Seitzer P, Sekiguchi T, Selman F, Serra-Ricart M, Sharp R, Snell RL, Snodgrass C, Stallard T, Stecklein G, Sterken C, Stüwe JA, Sugita S, Sumner M, Suntzeff N, Swaters R, Takakuwa S, Takato N, Thomas-Osip J, Thompson E, Tokunaga AT, Tozzi GP, Tran H, Troy M, Trujillo C, Van Cleve J, Vasundhara R, Vazquez R, Vilas F, Villanueva G, von Braun K, Vora P, Wainscoat RJ, Walsh K, Watanabe J, Weaver HA, Weaver W, Weiler M, Weissman PR, Welsh WF, Wilner D, Wolk S, Womack M, Wooden D, Woodney LM, Woodward C, Wu ZY, Wu JH, Yamashita T, Yang B, Yang YB, Yokogawa S, Zook AC, Zauderer A, Zhao X, Zhou X, Zucconi JM. Deep Impact: observations from a worldwide Earth-based campaign. Science 2005; 310:265-9. [PMID: 16150977 DOI: 10.1126/science.1118978] [Citation(s) in RCA: 158] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
On 4 July 2005, many observatories around the world and in space observed the collision of Deep Impact with comet 9P/Tempel 1 or its aftermath. This was an unprecedented coordinated observational campaign. These data show that (i) there was new material after impact that was compositionally different from that seen before impact; (ii) the ratio of dust mass to gas mass in the ejecta was much larger than before impact; (iii) the new activity did not last more than a few days, and by 9 July the comet's behavior was indistinguishable from its pre-impact behavior; and (iv) there were interesting transient phenomena that may be correlated with cratering physics.
Collapse
|
232
|
Zinner R, Barrett B, Volgin A, Gelovani J, Huang J, Tran H, Mills G, Hong W, Fu Y, Mao L. P-146 Higher order relationships and the medicinal algorithmic combinatorial screen (MACS). Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80640-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
233
|
Jang S, Tran H, Alavi A. SU-FF-I-45: Effects of Patient Positions On PET Tumor Volume Assessment in Lung Cancer. Med Phys 2005. [DOI: 10.1118/1.1997525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
234
|
Tran H, Joubert P, Bonamy L, Lavorel B, Renard V, Chaussard F, Faucher O, Sinardet B. Femtosecond time resolved coherent anti-Stokes Raman spectroscopy: experiment and modelization of speed memory effects on H2-N2 mixtures in the collision regime. J Chem Phys 2005; 122:194317. [PMID: 16161583 DOI: 10.1063/1.1894020] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
With the aim of temperature diagnostic, femtosecond time-resolved CARS (coherent anti-Stokes Raman spectroscopy) is applied to probe H2 in H2-N2 mixtures. In a first part, a Lorentzian profile is used to model the femtosecond CARS response. A difference between the experimental broadening and the expected one is observed in the collision regime. The observed broadening increases strongly in an inhomogeneous way with respect to the perturber concentration. This is of considerable importance for temperature measurements. In a second part, we show that in the collision regime, this inhomogeneous broadening is due to the speed dependence of the collisional parameters and the memory effects of the radiator speed. A new modelization of the time-resolved CARS response taking into account the speed memory effects is presented and applied to the temperature diagnostic in H2-N2 mixtures. The numerical results are in good agreement with experiments.
Collapse
|
235
|
Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23:2544-55. [PMID: 15753462 DOI: 10.1200/jco.2005.02.477] [Citation(s) in RCA: 422] [Impact Index Per Article: 22.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
PURPOSE Bevacizumab (Avastin; Genentech, South San Francisco, CA) is a recombinant, humanized anti-vascular endothelial growth factor monoclonal antibody. Erlotinib HCl (Tarceva, OSI-774; OSI Pharmaceuticals, New York, NY) is a potent, reversible, highly selective and orally available HER-1/epidermal growth factor receptor tyrosine kinase inhibitor. Preclinical data in various xenograft models produced greater growth inhibition than with either agent alone. Additionally, both agents have demonstrated benefit in patients with previously treated non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS A phase I/II study in two centers examined erlotinib and bevacizumab (A+T) in patients with nonsquamous stage IIIB/IV NSCLC with > or = one prior chemotherapy. In phase I, erlotinib 150 mg/day orally plus bevacizumab 15 mg/kg intravenously every 21 days was established as the phase II dose, although no dose-limiting toxicities were observed. Phase II assessed the efficacy and tolerability of A+T at this dose. Pharmacokinetic parameters were evaluated. ResultsForty patients were enrolled and treated in this study (34 patients at phase II dose); the median age was 59 years (range, 36 to 72 years), 21 were female, 30 had adenocarcinoma histology, nine were never-smokers, and 22 had > or = two prior regimens (three patients had > or = four prior regimens). The most common adverse events were mild to moderate rash, diarrhea, and proteinuria. Preliminary data showed no pharmacokinetic interaction between A + T. Eight patients (20.0%; 95% CI, 7.6% to 32.4%) had partial responses and 26 (65.0%; 95% CI, 50.2% to 79.8%) had stable disease as their best response. The median overall survival for the 34 patients treated at the phase II dose was 12.6 months, with progression-free survival of 6.2 months. CONCLUSION Encouraging antitumor activity and safety of A + T support further development of this combination for patients with advanced NSCLC and other solid tumors.
Collapse
|
236
|
Tran H, Petropoulos D, Worth L, Mullen CA, Madden T, Andersson B, Choroszy M, Nguyen J, Webb SK, Chan KW. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004; 10:805-12. [PMID: 15505611 DOI: 10.1016/j.bbmt.2004.07.010] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
We investigated the pharmacokinetics (PK) of a recently approved intravenous busulfan (IVBU) formulation as a part of the preparative regimen in 20 children with advanced hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation. Seventeen patients received a thiotepa, IVBU, and cyclophosphamide-based regimen, and 3 patients received an IVBU and cyclophosphamide-based regimen. All patients received IVBU 0.8 mg/kg for the first 2 doses; thereafter, the IVBU dose was modified, if required, to achieve a final area under the concentration-time curve (AUC) at steady state of 1150 micromol/L/min per dose (range, 1000-1300 micromol/L/min per dose; SD +/-13%) based on the first-dose PK determination. PK studies were repeated on subsequent doses to verify the final AUC. Initial mean IVBU clearance and half-life were 3.96 mL/min/kg and 1.98 hours, respectively. Sixteen (80%) of the 20 patients received dose adjustments: 14 patients required dose escalations, and 2 required dose reductions. Overall, thirteen (72%) of 18 available sample sets at final follow-up PK analysis showed the IVBU exposure to be within the targeted range. IVBU PK was linear, and interpatient variability was much lower than that observed with oral busulfan. IVBU was well tolerated, and no case of hepatic veno-occlusive disease was encountered. Mild and transient hyperbilirubinemia was observed in 7 patients. Thirteen of the 20 patients were alive at a median follow-up of 651 days (range, 386-1555 days). We conclude that a standardized IVBU dose of 0.8 mg/kg in children does not always result in an AUC within the reference range defined in this study. Therapeutic drug monitoring with dose adjustment based on first-dose PK can optimize the systemic busulfan exposure for children undergoing allogeneic hematopoietic stem cell transplantation.
Collapse
|
237
|
Schabowski S, Sciacca D, Tran H, Roberts R. Taking the hard line approach to hypertension education: do emergency department patients prefer it? Ann Emerg Med 2004. [DOI: 10.1016/j.annemergmed.2004.07.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
238
|
Lee HY, Han JY, Chang YS, Tran H, Kurie JM, Lotan R, Liu DD, Lee JJ, Lee JS, Hong WK. Implication of insulin-like growth factor (IGF)/IGF binding protein-3 and alpha-tocopherol in the chemopreventive activity of 9- cis retinoic acid in lung cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.1005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
239
|
Abstract
Imiquimod is being investigated as a therapeutic option for the management of actinic keratosis. Three recent clinical trials have demonstrated a reasonable efficacy rate and high safety profile. 'Cycle' therapy may improve the safety profile while maintaining efficacy. 'Field' treatment with imiquimod may uncover and treat 'subclinical' actinic keratoses, which in turn may potentially result in fewer recurrences. Longer follow-up studies are required to investigate this possibility.
Collapse
|
240
|
Abstract
Basal cell carcinoma is the most common malignancy among caucasians worldwide. Accurate epidemiological data can be difficult to obtain, but does suggest that the overall incidence is increasing. Risk factors include skin type, prior skin cancers and immunosuppression. Research in free radical-mediated cellular injury and innate defence mechanisms, and ultraviolet radiation-induced genetic mutations have improved our understanding of the development of this disorder.
Collapse
|
241
|
Gordon N, Mullen CA, Tran H, Worth L, Gomez Almaguer D, Chan KW. Fludarabine and once-daily intravenous busulfan for allogeneic bone marrow transplantation for Chediak-Higashi syndrome. J Pediatr Hematol Oncol 2003; 25:824-6. [PMID: 14528111 DOI: 10.1097/00043426-200310000-00019] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
An HLA-identical sibling bone marrow transplant was done for a patient with Chediak-Higashi syndrome. The preparative regimen included intravenous fludarabine (40 mg/m2/dx4) and busulfan (130 mg/m2/dx4). Busulfan was given once daily. Pharmacokinetic studies showed the area under the concentration-time curve of the once-daily intravenous busulfan was similar to that seen with the total daily dose administered with an every-6-hourly regimen. Toxicity was minimal. Myeloid engraftment occurred on day +17 and donor chimerism was complete. Fludarabine and once-daily intravenous busulfan is well tolerated and is adequate for engraftment of sibling transplant in Chediak-Higashi syndrome.
Collapse
|
242
|
Tran H. Mutant Nbs1 enhances cisplatin-induced DNA damage and cytotoxicity in head and neck cancer. Otolaryngol Head Neck Surg 2003. [DOI: 10.1016/s0194-5998(03)00977-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
243
|
|
244
|
Chan KW, Mullen CA, Worth LL, Choroszy M, Koontz S, Tran H, Slopis J. Lorazepam for seizure prophylaxis during high-dose busulfan administration. Bone Marrow Transplant 2002; 29:963-5. [PMID: 12098063 DOI: 10.1038/sj.bmt.1703593] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2002] [Accepted: 03/19/2002] [Indexed: 11/09/2022]
Abstract
Seizure is a recognized complication of high-dose busulfan (BU) therapy and phenytoin (DPH) is widely used as prophylaxis. A number of adverse effects have been associated with DPH and it may also interfere with BU metabolism. We used lorazepam (median dose 0.022 mg/kg) i.v. or p.o. before each dose and for 24 h after the last dose of BU as seizure prophylaxis to 29 children undergoing hematopoietic stem cell transplantation. The regimen was well tolerated and drowsiness was the only significant side-effect. Twelve patients were able to receive the entire prophylaxis by mouth. No seizure developed during and within 48 h of BU. Concomitant pharmacokinetic studies showed no alternation of the absorption and clearance of BU during lorazepam administration. Lorazepam can be used as an alternative for seizure prophylaxis during high-dose BU treatment.
Collapse
|
245
|
Slavcheva E, Albanis E, Jiao Q, Tran H, Bodian C, Knight R, Milford E, Schiano T, Tomer Y, Murphy B. Cytotoxic T-lymphocyte antigen 4 gene polymorphisms and susceptibility to acute allograft rejection. Transplantation 2001; 72:935-40. [PMID: 11571462 DOI: 10.1097/00007890-200109150-00032] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
BACKGROUND Cytotoxic T-lymphocyte antigen 4 (CTLA4) has been shown to play a critical role in the down-regulation of the immune response. We retrospectively examined the association between acute rejection and two polymorphisms in the CTLA4 gene, the dinucleotide (AT)n repeat polymorphism in exon 3 and the single nucleotide polymorphism A/G at position 49 in exon 1, in a cohort of liver and kidney transplant recipients. METHODS AND RESULTS A total of 207 liver and 167 renal transplant recipients were analyzed. In the case of the (AT)n repeat polymorphism we found an increased incidence of acute rejection in association with allele 3 and 4 in both liver and kidney (P=0.002 and 0.05, respectively). In addition, in liver transplant recipients, allele 7 was associated with acute rejection independent of ethnicity (P<0.05). Allele 1 was less frequently observed in African American as compared with Caucasian liver and kidney transplant recipients, with a frequency of 33.8% and 69%, respectively (P<0.0001). Those patients with allele 1 had a tendency toward a lower rate of rejection at 42% versus 57.8% (P=0.058), suggesting a potential protective effect of allele 1. Analysis of the A/G single nucleotide polymorphism demonstrated no association between either allele and the incidence of acute rejection in the patients studied. CONCLUSION These initial observations provide the necessary basis to further investigate the risk stratification of transplant recipients based on specific CTLA4 gene polymorphisms.
Collapse
|
246
|
Shah N, Oseth L, Tran H, Hirsch B, LeBien TW. Clonal variation in the B-lineage acute lymphoblastic leukemia response to multiple cytokines and bone marrow stromal cells. Cancer Res 2001; 61:5268-74. [PMID: 11431369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
The acquisition of genetic abnormalities in human B-lineage acute lymphoblastic leukemia (ALL) culminates in the clonal expansion of bone marrow (BM)-derived leukemic blasts. However, the response of leukemic cells to signals transduced by the BM microenvironment is not completely understood. The present study describes a new human B-lineage ALL cell line designated BLIN-4 (B LINeage-4). BLIN-4 cells respond to multiple cytokines/human BM stromal cell-derived molecules. One subline (BLIN-4E) undergoes cell death in the absence of BM stromal cells or cytokines and slowly proliferates on human BM stromal cells supplemented with interleukin (IL)-7 + FLT3-ligand. Another subline (BLIN-4L) slowly proliferates in the absence of cytokines and BM stromal cells and shows robust proliferation on BM stromal cells supplemented with IL-7 + FLT3-ligand. Although human BM stromal cells are comparable with IL-7 + FLT3-ligand in supporting proliferation of BLIN-4L cells, neutralizing antibody experiments demonstrate that BLIN-4L expansion on BM stromal cells is IL-7/FLT3-ligand independent. BLIN-4L could also respond to human thymic stromal lymphopoietin. BLIN-4E and BLIN-4L have the identical immunoglobulin heavy chain rearrangement and a CD10(+)/CD19(+)/CD20(-)/CD22(+)/CD40(+)/mu heavy chain(-) phenotype. The original BM leukemic blasts harbored a ring chromosome 4 with a low percentage of cells also having either trisomy 8 or trisomy 18. The BLIN-4 sublines maintained the ring chromosome 4, but the trisomy 8 and trisomy 18 segregated into BLIN-4E and BLIN-4L, respectively. Thus, the BLIN-4 sublines exhibit biological characteristics consistent with a potential evolution in B-lineage ALL involving subclones with decreasing requirements on the BM microenvironment.
Collapse
|
247
|
Zinner R, Glisson B, Pisters K, Khuri F, Oh Y, Ro J, Ordonez N, El-Naggar A, Tran H, Herbst R. Cisplatin and gemcitabine combined with herceptin in patients (pt) with her2 overexpressing, untreated, advanced, non-small-cell lung cancer (NSCLC): a phase II trial. Eur J Cancer 2001. [DOI: 10.1016/s0959-8049(01)81052-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
248
|
Chow MS, Fan C, Tran H, Zhao H, Zhou L. Effects of diaspirin cross-linked hemoglobin (DCLHb) during and post-CPR in swine. J Pharmacol Exp Ther 2001; 297:224-9. [PMID: 11259548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023] Open
Abstract
The purpose of the study was to test the hypothesis that diaspirin cross-linked hemoglobin (DCLHb) can produce improved resuscitation during cardiac arrest. DCLHb, a derivative of human hemoglobin, has previously been demonstrated to produce a vasopressor response that is associated with increased blood flow to vital organs. In addition, it is an oxygen carrier. These effects may be beneficial to extreme low flow states, such as that during cardiac arrest and cardiopulmonary resuscitation (CPR). Experimental cardiac arrest and CPR were carried out in 32 anesthetized immature pigs. In each animal, ventricular fibrillation was induced for 5 min, followed by 10 min of standard CPR with a pneumatic device and room air ventilation. High (15 ml/kg) and low (5 ml/kg) doses of DCLHb or equivalent volume of normal saline were infused at the beginning of CPR in a random and blind manner. Cardiac output, organ blood flow, aortic pressure, coronary perfusion pressure, blood gases, and lactate concentrations were obtained before and during CPR. Following the 10-min CPR, the animals were defibrillated and the return of spontaneous circulation (ROSC) determined. DCLHb treatment achieved 75% ROSC compared with 25% in the saline group (p < 0.05). In addition, a better (p < 0.05) myocardial O(2) delivery, venous blood O(2) content, and myocardial and cerebral perfusion pressure were observed in the DCLHb group. DCLHb treatment during cardiac arrest and CPR significantly improves ROSC. This is most likely related to its improvement in coronary perfusion and myocardial oxygen delivery.
Collapse
|
249
|
Zupancic ML, Tran H, Hofmeister AE. Chromosomal organization governs the timing of cell type-specific gene expression required for spore formation in Bacillus subtilis. Mol Microbiol 2001; 39:1471-81. [PMID: 11260465 DOI: 10.1046/j.1365-2958.2001.02331.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
During the early stages of spore formation in Bacillus subtilis, asymmetric division precedes chromosome segregation, such that the forespore transiently contains only about one-third of the genetic material surrounding the origin of replication. Shortly after septum formation, the transcription factor sigmaF initiates forespore-specific gene expression that is essential for the proteolytic activation of pro-sigmaE in the neighbouring mother cell. Moving the sigmaF-dependent spoIIR gene from its original origin-proximal position to an ectopic origin-distal site caused a delay in spoIIR transcription, as well as delays and reductions in the proteolytic activation of pro-sigmaE and sigmaE-directed gene expression. These defects correlated with the accumulation of disporic sporangia, thus reducing sporulation efficiency in a manner that depended upon the distance that spoIIR had been moved from the origin-proximal third of the chromosome. A significant proportion of disporic sporangia exhibited sigmaE activity in their central compartment, indicating that delays and reductions in sigmaE activation can lead to the formation of a second septum at the opposite pole. These observations support a model in which chromosomal spoIIR position temporally regulates sigmaE activation, thereby allowing for the rapid establishment of mother cell-specific gene expression that is essential for efficient spore formation. The implications of these findings for cell type-specific gene expression during the early stages of spore formation in B. subtilis are discussed.
Collapse
|
250
|
Shah D, Kelly J, Zhang Y, Dande P, Martinez J, Ortiz G, Fronza G, Tran H, Soto AM, Marky L, Gold B. Evidence in Escherichia coli that N3-methyladenine lesions induced by a minor groove binding methyl sulfonate ester can be processed by both base and nucleotide excision repair. Biochemistry 2001; 40:1796-803. [PMID: 11327842 DOI: 10.1021/bi0024658] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
It has been previously reported that a neutral DNA equilibrium binding agent based on an N-methylpyrrolecarboxamide dipeptide (lex) and modified with an O-methyl sulfonate ester functionality (MeOSO(2)-lex) selectively affords N3-methyladenine lesions. To study the interaction of the neutral lex dipeptide with calf thymus DNA, we have prepared stable, nonmethylating sulfone analogues of MeOSO(2)-lex that are neutral and cationic. Thermodynamic studies show that both the neutral and monocationic sulfone compounds bind to DNA with K(b)'s of 10(5) in primarily entropy-driven reactions. To determine how the cytotoxic N3-methyladenine adduct generated from MeOSO(2)-lex is repaired in E. coli, MeOSO(2)-lex was tested for toxicity in wild-type E. coli and in mutant strains defective in base excision repair (tag and/or alkA glycosylases or apn endonuclease), nucleotide excision repair (uvrA), and both base and nucleotide excision repair (tag/alkA/uvrA). The results clearly demonstrate the cellular toxicity of the N3-methyladenine lesion, and the protective role of base excision glycosylase proteins. A novel finding is that in the absence of functional base excision glycosylases, nucleotide excision repair can also protect cells from this cytotoxic minor groove lesion. Interaction between base and nucleotide excision repair systems is also seen in the protection of cells treated with cis-diamminedichloroplatinum(II) but not with anti-(+/-)-r-7,t-8-dihydroxy-t-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene.
Collapse
|